Related Experiment Video
Updated: Aug 4, 2025

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
Published on: August 16, 2020
Accumulation of α-synuclein mediates podocyte injury in Fabry nephropathy
Fabian Braun1,2, Ahmed Abed3, Dominik Sellung3
1III. Department of Medicine and.
Abstract:
Current therapies for Fabry disease are based on reversing intracellular accumulation of globotriaosylceramide (Gb3) by enzyme replacement therapy (ERT) or chaperone-mediated stabilization of the defective enzyme, thereby alleviating lysosomal dysfunction. However, their effect in the reversal of end-organ damage, like kidney injury and chronic kidney disease, remains unclear. In this study, ultrastructural analysis of serial human kidney biopsies showed that long-term use of ERT reduced Gb3 accumulation in podocytes but did not reverse podocyte injury. Then, a CRISPR/Cas9-mediated α-galactosidase knockout podocyte cell line confirmed ERT-mediated reversal of Gb3 accumulation without resolution of lysosomal dysfunction. Transcriptome-based connectivity mapping and SILAC-based quantitative proteomics identified α-synuclein (SNCA) accumulation as a key event mediating podocyte injury. Genetic and pharmacological inhibition of SNCA improved lysosomal structure and function in Fabry podocytes, exceeding the benefits of ERT. Together, this work reconceptualizes Fabry-associated cell injury beyond Gb3 accumulation, and introduces SNCA modulation as a potential intervention, especially for patients with Fabry nephropathy.
Insights
Current Fabry disease therapies reduce globotriaosylceramide (Gb3) but don't reverse kidney damage. This study reveals alpha-synuclein (SNCA) accumulation drives podocyte injury, suggesting SNCA modulation as a novel therapeutic target for Fabry nephropathy.
Area of Science:
- Nephrology
- Genetics
- Cell Biology
Background:
- Fabry disease therapies aim to reduce globotriaosylceramide (Gb3) accumulation and lysosomal dysfunction.
- The efficacy of current treatments in reversing established end-organ damage, particularly kidney injury, is not fully understood.
Purpose of the Study:
- To investigate the impact of enzyme replacement therapy (ERT) on podocyte injury in Fabry disease.
- To identify novel mechanisms underlying podocyte injury beyond Gb3 accumulation.
- To explore new therapeutic targets for Fabry nephropathy.
Main Methods:
- Ultrastructural analysis of human kidney biopsies.
- CRISPR/Cas9 gene editing to create α-galactosidase knockout podocytes.
- Transcriptome-based connectivity mapping and SILAC-based quantitative proteomics.
- Genetic and pharmacological inhibition of α-synuclein (SNCA).
Main Results:
- Long-term ERT reduced Gb3 in podocytes but did not reverse podocyte injury or fully restore lysosomal function.
- α-synuclein (SNCA) accumulation was identified as a key mediator of podocyte injury.
- Inhibition of SNCA improved lysosomal structure and function in Fabry podocytes, surpassing ERT benefits.
Conclusions:
- Fabry disease-associated podocyte injury involves mechanisms beyond Gb3 accumulation, notably SNCA accumulation.
- Modulating SNCA presents a promising therapeutic strategy for Fabry nephropathy, potentially offering greater benefits than current ERT.
More Related Videos
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Nephrotic Syndrome I : Introduction
Lysosomal Hydrolases
Nephrons
Renal Corpuscle
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...

